Dyne Therapeutics, Inc.
For the period ended May 30, 2025. Filed Apr 15, 2025.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
May 30, 2025 · Filed Apr 15, 2025
Use the contents to explore the available documents and sections.
Contents
Cover page
Show cover page
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No. )
Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐
Check the appropriate box:
| ☐ | Preliminary Proxy Statement |
|---|---|
| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| ☒ | Definitive Proxy Statement |
| ☐ | Definitive Additional Materials |
| ☐ | Soliciting Material under § 240.14a-12 |
Dyne Therapeutics, Inc.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check all boxes that apply):
| ☒ | No fee required |
|---|---|
| ☐ | Fee paid previously with preliminary materials |
| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |
DYNE THERAPEUTICS, INC.
1560 Trapelo Road
Waltham, Massachusetts 02451
(781) 786-8230
NOTICE OF 2025 ANNUAL MEETING OF STOCKHOLDERS
To Be Held on Friday, May 30, 2025
Dear Stockholder:
You are cordially invited to the 2025 Annual Meeting of Stockholders (the “2025 Annual Meeting”) of Dyne Therapeutics, Inc. The 2025 Annual Meeting will be held exclusively via the Internet in a virtual meeting format at www.proxydocs.com/DYN on Friday, May 30, 2025 at 11:00 a.m. Eastern Time. At the meeting, the stockholders will consider and vote on the following matters:
To elect two Class II directors, Edward Hurwitz and Dirk Kersten, each to serve for a three-year term expiring at the 2028 annual meeting of stockholders and until his respective successor has been duly elected and qualified;
To vote, on an advisory basis, to approve the compensation of our named executive officers;
To hold an advisory vote on the frequency of future advisory votes on the compensation of our named executive officers;
To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025; and
To transact any other business that may properly come before the 2025 Annual Meeting or any adjournment or postponement thereof.
You may attend the 2025 Annual Meeting online atwww.proxydocs.com/DYN, where you will be able to vote your shares electronically during the meeting and submit questions during the meeting. Stockholders will not be able to attend the annual meeting in person. In order to attend the 2025 Annual Meeting online, you must register in advance at www.proxydocs.com/DYNprior to the commencement of the 2025 Annual Meeting. Upon completing your registration, you will receive further instructions via email, including a unique link that will allow you access to the 2025 Annual Meeting and to vote and submit questions during the 2025 Annual Meeting. Please follow the instructions found on your Notice Regarding the Availability of Proxy Materials, Proxy Card and/or Voting Instruction Card and subsequent instructions that will be delivered to you via email.
Stockholders of record at the close of business on April 4, 2025 will be entitled to notice of and to vote electronically during the 2025 Annual Meeting or any adjournment or postponement thereof. A list of registered stockholders as of the close of business on the record date will be available for examination by any stockholder for any purpose germane to the 2025 Annual Meeting during normal business hours at our principal executive offices at 1560 Trapelo Road, Waltham, Massachusetts 02451 during the 10-day period ending on the day before the 2025 Annual Meeting. We have elected to provide access to our proxy materials over the Internet under the Securities and Exchange Commission’s “notice and access” rules. We believe that providing our proxy materials over the Internet expedites stockholders’ receipt of proxy materials, lowers costs and reduces the environmental impact of our annual meeting.
We encourage all stockholders to attend the 2025 Annual Meeting online. However, whether or not you plan to attend the 2025 Annual Meeting, we encourage you to read the proxy statement and submit your proxy or voting instructions as soon as possible. Please review the instructions on each of your voting options described in the proxy statement.
By the Order of the Board of Directors,
/s/ John G. Cox
John G. Cox
President and Chief Executive Officer
Waltham, Massachusetts
April 15, 2025
Important Notice Regarding Internet Availability of Proxy Materials for the 2025 Annual Meeting of Stockholders to be Held on May 30, 2025: The proxy materials and our 2024 Annual Report to Stockholders, which includes our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, are available atwww.proxydocs.com/DYN. These documents are also available to any stockholder who wishes to receive a paper copy by calling 866-648-8133, visitingwww.investorelections.com/DYN or emailing paper@investorelections.com. Any requests for a paper copy of these documents should be received by May 17, 2025, in order to ensure timely delivery.
TABLE OF CONTENTS
| PROXY STATEMENT 2025 Annual Meeting OF STOCKHOLDERS | 1 |
|---|---|
| IMPORTANT INFORMATION ABOUT THE ANNUAL MEETING AND VOTING | 2 |
| PROPOSAL NO. 1—ELECTION OF DIRECTORS | 8 |
| CORPORATE GOVERNANCE | 11 |
| Committees of Our Board of Directors | 15 |
| Director Compensation | 18 |
| Report of the Audit Committee of the Board of Directors | 21 |
| PROPOSAL NO. 2—ADVISORY VOTE ON THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS | 22 |
| PROPOSAL NO. 3—ADVISORY VOTE ON THE FREQUENCY OF FUTURE ADVISORY VOTES ON THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS | 23 |
| EXECUTIVE OFFICERS | 24 |
| EXECUTIVE COMPENSATION | 25 |
| Compensation Discussion and Analysis | 25 |
| Compensation Committee Report | 38 |
| Summary Compensation Table | 38 |
| Compensation Tables | 40 |
| Employment and Other Arrangements with Our Named Executive Officers and Chief Executive Officer | 43 |
| Pay Versus Performance | 48 |
| SECURITIES AUTHORIZED FOR ISSUANCE UNDER OUR EQUITY COMPENSATION PLANS | 51 |
| TRANSACTIONS WITH RELATED PERSONS | 52 |
| PROPOSAL NO. 4—RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTANTS | 55 |
| SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT | 56 |
| DELINQUENT SECTION 16(A) REPORTS | 58 |
| STOCKHOLDER PROPOSALS FOR OUR 2026 ANNUAL MEETING | 59 |
| HOUSEHOLDING OF ANNUAL MEETING MATERIALS | 59 |
DYNE THERAPEUTICS, INC.
1560 Trapelo Road
Waltham, Massachusetts 02451
(781) 786-8230
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.